Shanghai Jahwa United Co (600315) Fair Value & Analysis
Consumer Defensive · CN · Market cap 12.6B CNY
Analysis
Shanghai Jahwa United Co (600315) currently trades at ¥17.43, while our model-based Fair Value estimate is ¥6.77 — implying the stock looks roughly 61.2% overvalued today. We read business quality at 90/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Shanghai Jahwa United Co., Ltd. engages in the research and development, production, and sale of daily chemical products, and baby products in the People's Republic of China and internationally. It offers skin care, cleaning, home care, and infant feeding products under the Liushen, Yuze, Herborist, Maxam, GUOFU, Jiaan, Qichu, and Tommee Tippee brands. The company also provides technical services for daily chemicals and cosmetics. The company also provides research, development, and technology transfer services for pharmaceuticals, packaging containers, fragrances, hygiene products, disinfection products, detergents, oral hygiene products, paper products, wet wipes, wax products, insect repellent products, and electrical devices for insect repellent, as well as beauty and hairdressing products and services. It operates e-commerce channels, sales of maternal and infant care products, and cosmetics stores, as well as sells its products in department stores and supermarkets. The compan…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.